Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iSPOT-A ADHD biomarker and methylphenidate response study
NL-OMON33496Phase 4Active, not recruiting
- Sponsor
- Brain Resource
- Start
- Oct 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of methylphenidate in attention deficit hyperactivity disorder (ADHD) (2 cohorts), sponsored by Brain Resource. Primary endpoints: Objective markers distinguishing ADHD from healthy controls, Predictors of treatment response to methylphenidate and 2 more. Started Oct 2009; status: active, not recruiting.
02
Drugs
methylphenidate
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NL-OMON33496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33496.